655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations

被引:0
|
作者
Tommasi, Stefania
Fedele, Vita
Lacalamita, Rosanna
Bruno, Michele
Schittulli, Francesco
Ginzinger, David
Scott, Gery
Eppenberger-Castori, Serenella
Calistri, Daniele
Casadei, Silvia
Seymour, Ian
Longo, Salvatore
Giannelli, Gianluigi
Pilato, Brunella
Simone, Giovanni
Benz, Christopher C.
Paradiso, Angelo
机构
[1] Natl Canc Inst, Clin Expt Oncol Lab, I-70126 Bari, Italy
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Stiftung Tumorbank Basel, Basel, Switzerland
[4] Buck Inst Age Res, Novato, CA USA
[5] Inst Oncol Romagnolo Forli, Ravenna, Italy
[6] Univ Bari, Bari, Italy
关键词
single nucleotide polymorphism; ERBB2; breast cancer; familiarity; risk;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human ERBB2 presents several SNPs. One of these, Ile655Val, introduces a structural change in the transmembrane region of ERBB2 and has been the focus of debate over its potential role as a susceptibility marker for breast cancer risk. Another SNP, Ala1170Pro, introduces a structural change in the carboxyl-terminal regulatory domain of the protein, but its clinical and biological importance remains undefined. The aim of this study was to investigate the association of rare alleles of both SNPs and the risk of developing breast cancer, BRCA1 alterations and clinical-pathological features of Caucasian breast cancer patients with familial history of breast/ovarian cancer. The originality of the present paper is that it is the only specifically focusing on the relationship between ERBB2 SNPs and familiarity/BRCA1 characteristics. A consecutive series of 628 patients with first diagnosis of breast cancer and 169 healthy people had DNA analyzed for both SNPs. Genotypic or allelic frequencies of ERBB2 SNPs in breast cancer patients were similar than in controls. The variant allele 655Val was significantly associated with younger age (p = 0.009) particularly associated with patient family history of breast cancer (p = 0.02). The 655Val allele was also more commonly found in invasive, while the variant 1170Pro in estrogen receptor positive breast cancers. Furthermore, this last SNP seems to be strictly associated with the presence of BRCA1 polymorphisms. In conclusion, these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 50 条
  • [31] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Osorio, Ana
    Ramon y Cajal, Teresa
    Baiget, Montserrat
    Lasa, Adriana
    Diaz-Rubio, Eduardo
    de la Hoya, Miguel
    Caldes, Trinidad
    Teule, Alex
    Lazaro, Conxi
    Blanco, Ignacio
    Balmana, Judith
    Sanchez-Olle, Gessami
    Vega, Ana
    Blanco, Ana
    Chirivella, Isabel
    Esteban Cardenosa, Eva
    Duran, Mercedes
    Velasco, Eladio
    Martinez de Duenas, Eduardo
    Tejada, Maria-Isabel
    Miramar, Maria-Dolores
    Calvo, Maria-Teresa
    Guillen-Ponce, Carmen
    Salazar, Raquel
    San Roman, Carlos
    Urioste, Miguel
    Benitez, Javier
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 221 - 232
  • [32] BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica
    Gutierrez Espeleta, G. A.
    Llacuachaqui, M.
    Garcia-Jimenez, L.
    Aguilar Herrera, M.
    Loaiciga Vega, K.
    Ortiz, A.
    Royer, R.
    Li, S.
    Narod, S. A.
    CLINICAL GENETICS, 2012, 82 (05) : 484 - 488
  • [33] Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Kotsopoulos, J
    Lubinski, J
    Lynch, HT
    Neuhausen, SL
    Ghadirian, P
    Isaacs, C
    Weber, B
    Kim-Sing, C
    Foulkes, WD
    Gershoni-Baruch, R
    Ainsworth, P
    Friedman, E
    Daly, M
    Garber, JE
    Karlan, B
    Olopade, OI
    Tung, N
    Saal, HM
    Eisen, A
    Osborne, M
    Olsson, H
    Gilchrist, D
    Sun, P
    Narod, SA
    CANCER CAUSES & CONTROL, 2005, 16 (06) : 667 - 674
  • [34] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Roger L. Milne
    Ana Osorio
    Teresa Ramón y Cajal
    Montserrat Baiget
    Adriana Lasa
    Eduardo Diaz-Rubio
    Miguel de la Hoya
    Trinidad Caldés
    Alex Teulé
    Conxi Lázaro
    Ignacio Blanco
    Judith Balmaña
    Gessamí Sánchez-Ollé
    Ana Vega
    Ana Blanco
    Isabel Chirivella
    Eva Esteban Cardeñosa
    Mercedes Durán
    Eladio Velasco
    Eduardo Martínez de Dueñas
    María-Isabel Tejada
    María-Dolores Miramar
    María-Teresa Calvo
    Carmen Guillén-Ponce
    Raquel Salazar
    Carlos San Román
    Miguel Urioste
    Javier Benítez
    Breast Cancer Research and Treatment, 2010, 119 : 221 - 232
  • [35] Differential Gene Expression of BRCA1, ERBB2 and TP53 Biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer Patients
    Zghair, Abdulrazzaq Neamah
    Sinha, Deepak Kumar
    Kassim, Arkan
    Alfaham, Mohmmad
    Sharma, Anil K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2016, 16 (04) : 519 - 525
  • [36] Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk
    Tilanus-Linthorst, Madeleine M. A.
    Lingsma, Hester F.
    Evans, D. Gareth
    Thompson, Deborah
    Kaas, Reinoutje
    Manders, Peggy
    van Asperen, Christi J.
    Adank, Muriel
    Hooning, Maartje J.
    Lim, Gek E. Kwan
    Eeles, Rosalind
    Oosterwijk, Jan C.
    Leach, Martin O.
    Steyerberg, Ewout W.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (01) : 156 - 163
  • [37] Familial Breast Cancer Clinical Response to Induction Chemotherapy or Radiotherapy Related to BRCA1/2 Mutations Status
    Fourquet, Alain
    Stoppa-Lyonnet, Dominique
    Kirova, Youlia M.
    Sigal-Zafrani, Brigitte
    Asselain, Bernard
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (02): : 127 - 131
  • [38] Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer
    C. B. Mainor
    C. Isaacs
    Current Breast Cancer Reports, 2020, 12 : 66 - 74
  • [39] Association of BRCA1 K1183R Polymorphism with Survival in BRCA1/2-Negative Chinese Familial Breast Cancer
    Pei, Renguang
    Wang, Peng
    Zhou, Yunfeng
    Zhang, Juan
    Ouyang, Tao
    Li, Benyao
    Xie, Yuntao
    CLINICAL LABORATORY, 2014, 60 (01) : 47 - 53
  • [40] Breast cancer risk associated with BRCA1/2 variants in the Pakistani population
    Abbas, Saba
    Siddique, Ayesha
    Shahid, Naeem
    Khan, Rabbia Tariq
    Fatima, Warda
    BREAST CANCER, 2019, 26 (03) : 365 - 372